Introduction: Health-related quality of life (HRQoL) is an important part of the clinical assessment and management of psoriasis. Few studies have investigated the effects of withdrawing treatment on the relationship between HRQoL and objective clinical manifestations of psoriasis. This post hoc subanalysis of a clinical trial (REVEAL) examined the relationship of HRQoL [assessed with the Dermatology Life Quality Index (DLQI)] and objective disease activity [assessed with the Psoriasis Area and Severity Index (PASI)] among patients before and after they underwent protocol-mandated discontinuation of psoriasis therapy.
discontinuation of therapy (week 52) compared with early in treatment (week 4). There was a significant interaction (P\0.0001) between the PASI-DLQI correlation and study period (week 4 or 52).
Conclusion: Discontinuing therapy in patients who initially responded to treatment, as seen in this analysis with adalimumab, disproportionately worsened patient-reported HRQoL relative to the worsening of PASI.
INTRODUCTION
Psoriasis is a major inflammatory disease with significant associated comorbidities, including cardiovascular disease, inflammatory bowel disease, metabolic syndrome, and psoriatic arthritis [1] . Health-related quality of life (HRQoL) is increasingly recognized as an important element of the overall clinical assessment of psoriasis rather than simply an adjunct to objective measures of disease [2] . The Dermatology Life Quality Index (DLQI) is a short, self-administered, dermatology-specific questionnaire that is the most commonly used tool to evaluate HRQoL in psoriasis clinical research [2, 3] . Objective clinical manifestations of psoriasis are commonly assessed with the Psoriasis Area and Severity Index (PASI), a validated scale that has been demonstrated to quantify clinical improvement in response to treatment [4, 5] .
Although it is difficult to correlate absolute values of the PASI and DLQI, several studies have explored the relationship between reductions in the objective severity of psoriasis as measured with the PASI and improvements in HRQoL as measured with the DLQI [6] . In secondary analyses of 1,469 patients with moderate-to-severe plaque psoriasis from two clinical trials of the tumor necrosis factor (TNF) inhibitor adalimumab, a 90% or greater improvement in the PASI (PASI 90 response) was associated with a greater improvement in the DLQI than that associated with a 75% or greater improvement in the PASI (PASI 75 response) [7] . Further, a study of the TNF inhibitor infliximab for severe plaque psoriasis demonstrated that the percent change in the PASI and the percent change in the DLQI for the combined infliximab and placebo groups were strongly correlated (Spearman's correlation of 0.61) [8] relative to baseline (week 0) and a C6-point increase in the PASI score compared with week 33] at a significantly higher rate than patients who were randomized to continue active treatment (28% vs. 5%; P\0.001) [11] . We hypothesized that patients who had achieved a clinical response in REVEAL and whose treatment was then discontinued would experience a worsening of dermatologyspecific HRQoL out of proportion to the worsening of the objective signs of disease.
METHODS

Study Design
This was a post hoc analysis of a phase 3, multicenter, 52-week, double-blind, placebocontrolled trial (REVEAL) performed at 81 sites across the USA and Canada (Clinicaltrials.gov #NCT00237887) [11] . The protocol was approved by the institutional review board of each participating medical center. The REVEAL study consisted of three treatment periods ( Fig. 1 ). In period A (weeks 0-16), patients were 
Patients
Males and females aged 18 years or older with a clinical diagnosis of moderate-to-severe plaque psoriasis (affected body surface area C10%) for at least 6 months were eligible for the REVEAL study [11] . PASI scores of 12 or greater and Physician's Global Assessment of at least ''moderate'' were required for eligibility. Key exclusion criteria included previous exposure to any systemic anti-TNF therapy and the inability to discontinue phototherapy or topical or systemic therapies. All patients provided written informed consent.
Efficacy Assessments
The DLQI consists of four components: symptoms and feelings (DLQIS); daily activities (DLQID); leisure (DLQIL); and personal relationships (DLQIP). DLQI total scores may range from 0 to 30, with a higher score indicating poorer HRQoL. A DLQI total score of more than 5 indicates a moderate effect of psoriasis on patient HRQoL; a DLQI score of more than 10 indicates a very large effect; and a DLQI score of more than 20 indicates an extremely large effect [12] . Thus, a DLQI total score of more than 10 supports the need for a more aggressive intervention. PASI scores may range from 0 to 72, with higher scores indicating greater disease severity. Post hoc comparisons of DLQI and PASI scores were evaluated at baseline, early in treatment (week 4), at the last point when all patients had at least a PASI 75 response (week 33), and after randomized treatment discontinuation (up to 19 weeks after discontinuation).
Statistical Analysis
Patients who received adalimumab during period A, achieved PASI 75 responses at week 16 and week 33, and were subsequently rerandomized to placebo during period C were the focus of this subanalysis. Missing data were imputed using the last observation carried forward. The correlation between DLQI component or total score and PASI score at weeks 4 and 52 was analyzed by linear regression using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). No other statistical hypothesis testing was conducted for this post hoc analysis.
RESULTS
Patients
Demographic and baseline disease activity characteristics of patients (N = 240) in the subanalysis population (Table 1) generally similar to those of patients in the overall study population [11] . The mean age of patients was approximately 43 years; most patients were male and nearly all were white. Baseline disease characteristics were consistent with moderate-to-severe psoriasis; the mean DLQI score at baseline (11.6) was [10, suggesting that, on average, psoriasis had a very large effect on HRQoL.
PASI Response
The proportion of patients with PASI 75, PASI 90, or PASI 100 responses decreased after discontinuation of therapy (Fig. 2 week 33 to 20.3% at week 52, and the PASI 100 response rate decreased from 37.9% at week 33 to 8.4% at week 52. Thus, discontinuation of therapy at week 33 resulted in recurrence of psoriasis symptoms by week 52.
PASI vs. DLQI
Mean PASI and DLQI scores at baseline, week 4,
week 33, and week 52 are reported in Fig. 3 . Mean PASI scores decreased from baseline to week 4 and continued to decline until week 33, indicating improvement in psoriasis symptoms. Mean PASI score increased from week 33 to week 52, indicating recurrence of disease symptoms upon discontinuation of treatment.
Mean DLQI scores followed a similar pattern.
However, although the mean PASI score at week 52 (6.7) remained lower than the PASI score at week 4 (8.0), the mean DLQI score at week 52 (5.3) was higher than at week 4 (4.3). Therefore, at the end of the study, PASI scores remained lower (indicating an improvement) compared with early treatment, whereas the mean DLQI To examine the association between the PASI and DLQI, the correlation between PASI scores and DLQI scores was evaluated by linear regression early in treatment (week 4) and
19 weeks after discontinuation of therapy (week 52). For every unit increase in PASI score, there was a disproportionately larger increase (i.e., worsening) in DLQI total score at week 52 compared with week 4 (Fig. 4) clinical experience, the erosion of HRQoL after treatment interruption may be a primary factor in influencing patients to reinitiate therapy. In support of these considerations, a recent systematic review concluded that continuous therapy is preferred for maintenance of disease control and HRQoL [17] .
This study benefited from a double-blind design that may have minimized bias by masking assignment to continue adalimumab or receive placebo; this was probably particularly important for a subjective, patientreported outcome such as the DLQI. Additional strengths were that the study was conducted at a large number of centers and that many patients were analyzed. Limitations of the study are that it was a post hoc analysis and, therefore, potentially subject to bias. Additionally, the comparison of PASI and DLQI scores was not evaluated beyond the relatively short period of 19 weeks after discontinuation of treatment. Finally, inherent limitations of the DLQI and PASI have been reported. Problems with the DLQI include inadequate measurement of mild illness, interpretability that has been rated only ''acceptable,'' and differential item functioning by disease, age, and sex [3, 18] . Although the PASI is the most thoroughly validated scale for psoriasis and is used extensively in clinical trials [4] , it has been criticized for having a nonlinear scale, poor sensitivity, and lack of standardization for translation into corresponding clinical severity categories [19] .
PASI scores on the lower end of the range (PASI \10) are less meaningful, so comparisons with DLQI scores among patients with low PASI scores may be more difficult. Furthermore, consistency and reliability of the PASI are influenced by the experience level of the physician [20] . Due to these limitations, this analysis must be considered exploratory and hypothesis generating; a prospective study would be needed to confirm the findings.
CONCLUSION
Discontinuing therapy, as observed in this analysis with adalimumab, has several negative effects in patients with psoriasis, including a loss of objective response and a disproportionately large negative impact on HRQoL. Interruption of treatment will likely result in an increase of psoriasis symptoms and a disproportionate decrease in HRQoL.
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